Recurrent Platinum-resistant Ovarian Cancer
7 clinical trials · Condition
◉ Watch Recurrent Platinum-resistant Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer (NCT05145218) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-09-28 |
| Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer (NCT04068974) | Peking Union Medical College Hospital | 2019-10-28 |
| Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. (NCT03467178) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-07-30 |
| A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (NCT03398655) | Vascular Biogenics Ltd. operating as VBL Therapeutics | 2017-12-19 |
| Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients (NCT02028117) | Akamis Bio | 2014-06-01 |
Track Recurrent Platinum-resistant Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.